Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Castle Biosciences (CSTL) announced a study validating its DecisionDx-Melanoma test published in the Journal of the American Academy of Dermatology. The test integrates tumor biology with clinicopathologic factors to provide personalized risk estimates for melanoma recurrence. Key findings include that 44% of patients could avoid sentinel lymph node biopsies without compromising survival rates exceeding 98%. The proprietary algorithm demonstrated a multivariate hazard ratio of 20.00 for predicting melanoma-specific survival, suggesting enhanced decision-making in cancer management.
Castle Biosciences (Nasdaq: CSTL) presented a framework for its diagnostic gene expression profile tests, MyPath Melanoma and DiffDx-Melanoma, aimed at enhancing clinical decision-making for melanoma diagnoses during the Maui Derm NP+PA Fall 2022 Conference. The proposed clinical workflow highlights how these tests can reduce diagnostic uncertainty, particularly in distinguishing between benign and malignant melanocytic lesions. The tests demonstrated a significant reduction in unnecessary excisions for benign results and increased visits for malignant cases, thus offering personalized treatment plans.
Castle Biosciences announced its three-year financial targets during an Investor Day event, projecting total revenue of $255-$330 million and positive net operating cash flow by December 31, 2025. The company emphasizes its foundational principles of exceptional employees and continuous improvement as essential for achieving these goals. Castle's leaders expressed confidence in their strong balance sheet and growth strategies, which include investments in innovative tests for dermatology, gastroenterology, and mental health.
Castle Biosciences (NASDAQ: CSTL) has been honored with the 2022 AZBio Fast Lane Award for its significant growth and commitment to patient care over the past 18 months. The company saw its workforce more than double, expanding from 201 to over 480 employees. Key achievements include strategic acquisitions in gastroenterology and mental health, the publication of 22 peer-reviewed papers, and a collaboration with the National Cancer Institute revealing a 27% improvement in survival rates for melanoma patients tested with DecisionDx-Melanoma.
Castle Biosciences (CSTL) will present at Baird’s 2022 Global Healthcare Conference on Sept. 13, 2022, at 2:00 p.m. ET. The presentation, led by CEO Derek Maetzold and CFO Frank Stokes, will be available via a live audio webcast on their website, with a replay for 90 days. Additionally, they will participate in one-on-one investor meetings at the Lake Street Best Ideas Growth Conference on Sept. 14, 2022. Castle is focused on diagnostics for conditions like skin cancers and Barrett’s esophagus.
Castle Biosciences, Inc. (CSTL) will host an Investor Day on Sept. 20, 2022, from 4:00 p.m. to 6:30 p.m. EDT, featuring insights on corporate strategy, growth plans, and financial outlook. Key executives, including Derek Maetzold and Frank Stokes, will lead the discussions. Attendees can register for the virtual event via the company's investor relations page. Castle focuses on innovative diagnostic tests for various health conditions, aiming to enhance patient care.
Castle Biosciences (CSTL) reported a 53% increase in Q2 2022 revenue to $34.8 million, alongside a 57% rise in total test reports delivered. The firm raised its full-year revenue guidance to $130–135 million. Key test volumes included 7,125 DecisionDx-Melanoma reports, up 39%, and 1,344 DecisionDx-SCC reports, up 71%. Despite positive revenue growth, net loss for Q2 was $(1.6) million, an improvement from $(8.8) million in 2021. Cash and equivalents stood at $273 million as of June 30, 2022.
Castle Biosciences (NASDAQ: CSTL) announced that the American Gastroenterological Association recognizes its TissueCypher® Barrett’s Esophagus test as beneficial for risk stratification in patients with non-dysplastic Barrett’s esophagus. This test aims to predict progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC). The AGA's best practice advice highlights the potential of TissueCypher to enhance clinical decision-making, identifying high-risk patients who may benefit from tailored treatment plans. This represents a significant advancement in managing Barrett’s esophagus.
Castle Biosciences (NASDAQ: CSTL) is set to present a company overview at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 1:00 p.m. Eastern time. The presentation will be led by Derek Maetzold, CEO, and Frank Stokes, CFO. Investors can access a live audio webcast on the company's website, with a replay available for two weeks thereafter. Castle specializes in innovative diagnostics for various health conditions, including skin cancers and mental health issues, driving advancements in patient care.
Castle Biosciences, Inc. (CSTL) will release its financial results for Q2 and six months ending June 30, 2022, after market close on August 8, 2022. A conference call to discuss the results is scheduled for 4:30 p.m. Eastern Time on the same day. The webcast will be available on the company's Investor Relations page. Castle specializes in diagnostics, focusing on innovative tests for skin cancers and other conditions, with ongoing research in new test developments.